CLONTECH Laboratories, Inc. Prevails in Patent Infringement Suit Against Life Technologies, Inc.

Jul 20, 1999, 01:00 ET from Clontech Laboratories, Inc.

    PALO ALTO, Calif., July 20 /PRNewswire/ -- In a decision rendered
 July 16, the U.S. District Court of the District of Maryland held that U.S.
 Patent Nos. 5,244,797 and 5,668,005, assigned to Life Technologies, Inc.
 (LTI), are unenforceable due to LTI's breach of its duty of candor to the U.S.
 Patent and Trademark Office.
     CLONTECH Laboratories, Inc. of Palo Alto, California, a biotechnology
 company which provides gene discovery tools to the biotechnology research
 market, was sued by LTI in December 1996 for infringement of the 5,244,797 and
 5,668,005 patents, as well as for breach of a label license agreement.  The
 technology at issue involves certain reverse transcriptase enzymes used in the
 cloning of cDNA molecules.
     The trial on the inequitable conduct issue, which took place in the
 Southern District of Maryland, Greenbelt Division, before the Honorable Judge
 Alexander Williams Jr., began on July 13.  On July 16, the court rendered a
 decision in CLONTECH's favor holding that the patent applicants and their
 representatives had intentionally withheld material information and had made
 affirmative misrepresentations to the PTO examiner.
     In response to the decision, Dr. Kenneth Fong, CEO of Clontech, stated,
 "We are delighted that after two and a half years of litigation we have
 prevailed.  This is great news for the biotech industry as a whole."
     CLONTECH was represented by lead attorney Marc R. Labgold, and attorneys
 Sharon E. Crane, Mark S. Kaufman, Catherine B. Richardson and Kevin Bell from
 the Washington, D.C. office of Long Aldridge & Norman, LLP.
     Still pending is a suit filed by CLONTECH in December 1998 in the U.S.
 District Court in Wilmington, Delaware against LTI.  In the Delaware action,
 CLONTECH alleges that Life Technologies knowingly and willfully marketed its
 SuperScript and SuperScript II products with a false patent marking, as well
 as committing other deceptive trade practices.
     For further information regarding this matter, please contact
 Sarah Brashears, Esq., Director of Intellectual Property at Clontech
 (800-662-2566, ext. 1188).
     CONTACT:  Sarah Brashears, Esq., Director of Intellectual Property of
 Clontech Laboratories, Inc., 800-662-2566, ext. 1188.

SOURCE Clontech Laboratories, Inc.